Highlights•MR antagonists (MRAs) have multiple protective actions in cardiac, renal and
vascular diseases.•The new MRA finerenone has greater potency and selectivity for MR,
compared to traditional MRAs.•Clinical trails show benefits of finerenone are associated with
less hyperkalaemia.•The molecular mechanisms of new MRAs are being defined in multiple
experimental systems.Mineralocorticoid receptor antagonists (MRAs) are best known as
potassium-sparing diuretics due to their blockade of aldosterone action in renal epithelial …